Ablynx has gotten positive results for its candidate (ALX-0171) in Phase I/IIa trial for infants infected with a life-threatening virus – respiratory syncytial virus (RSV).
Located near Ghent (Belgium), Ablynx is making advances in its Nanobody platform, based on the shorter monoclonal antibodies of llamas.
Due to their small size, these Nanobodies can be used in a whole new range of pharmaceutical applications – including nebulisation.
This is what Ablynx did for its wholly-owned Nanobody ALX-0171, that is being delivered by inhalation to young children infected with respiratory syncytial virus (RSV).
Now, Ablynx has positive topline results from its Phase I/IIa trial, which enrolled 53 infants aged 1 to 24 months which were hospitalised because of RSV.
The trial met its primary endpoint, which was to show that daily inhalation dose of ALX-0171 is safe and tolerated by infants.
This Nanobody had already shown a good safety profile in adults (in a previous Phase I trial),